Utilizing cytotoxic proteins linked to tumor targeting molecules as anti-tumor drugs is a promising approach. However, most cytotoxins derived from bacteria or plants have inherent problems such as large molecular weights and they trigger a strong immune system reaction, which leads to drug failure and serious side effects. Amphinase (Amph) is a ribonuclease with a low molecular weight that is found in northern leopard frog oocytes. It has strong cytotoxicity against tumor cell lines in vitro and weak immunogenicity in vivo, and is a promising candidate in the development of targeted drugs. Transforming growth factor-α (TGF-α) that binds to the epidermal growth factor receptor (EGFR) is being used as a targeting molecule for the treatment of EGFR high-expressing tumors. In this study, we expressed and purified a recombinant amphinase and its TGF-α fusion protein (AGT) separately from Escherichia coli. AGT exhibited more significant cytotoxicity in vitro on EGFR high-expressing tumor cell lines, and stronger anti-tumor effects in vivo. This fusion protein also exhibited unusual thermostability, low in vivo immunogenicity, and side effects. Our results provide a new entry point for the development of novel, highly efficient anti-tumor targeting biological agents with low immunogenicity.
Introduction
Targeted cytotoxins are currently among the most important strategies in anti-tumor drug development [1] . However, due to the strong immunogenicity of most toxic proteins derived from bacteria or plants, cancer patients rapidly produce neutralizing antibodies during their systemic treatments [2, 3] . Immunogenicity has become the bottleneck in the development of targeted cytotoxins, which has resulted in their current major applications being limited to leukemia and brain tumors [4, 5] .
To solve these problems, some researchers had begun to consider substituting the toxic proteins with humanized or low immunogenic enzymes [6, 7] . To date, the most successful immune toxins with low immunogenicity have mainly been constructed from amphibian ribonucleases [8] . Among them, onconase (Onc) and amphinase (Amph) derived from Rana pipiens oocytes have attracted much attention in the field of tumor therapy because of their low molecular weights and high anti-tumor efficiency [9] . Onconase is the first ribonuclease introduced into clinical use, and it has been approved by the USA, the European Union, and Australia as an orphan drug for the treatment of malignant mesothelioma [10] . In contrast, the study of Amph is just beginning, whose modification is rarely reported.
Thus, we hoped that this research can provide more valuable information for further study.
Amph consists of 114 amino acids and four pairs of disulfide bonds and has four different variants with a molecular weight of between 12.968 and 13.077 kDa. It has 40% similarity with Onc in the amino acid sequence [11] . In this study, Amph2 was selected. Amph2 is stable and has similar biological properties to Onc [11] , including significant toxicity towards cancer cells.
The epidermal growth factor receptor (EGFR) is a cell surface receptor of a class of extracellular protein ligands called the epidermal growth factor family (referred to as the 'EGF family') [12] . It is highly expressed and active in many cancer cells [12] , including around 30% of epithelial tumors, indicating that it is a good treatment target for a wide range of tumors [13] . As one of the specific binding factors for EGFR, transforming growth factor-α (TGF-α) is widely used in targeted anti-tumor drug research and development [14] . Early in 1994, Pastan Laboratories reported that Pseudomonas exotoxin A was successfully targeted to tumor cells after substituting the binding domain of the toxin with TGF-α [15, 16] . Based on this concept, we constructed a new immunoRNase by fusion of mature TGF-α peptide to the C terminus of Amph2 (named AGT) and explored its potential anti-tumor effect.
Materials and Methods

Ethics statement
Mice in the experiments were housed in a specific pathogen-free environment, which were performed in accordance with institutional guidelines and approved by the Institutional Animal Care and Use Committee in Shanghai Research Center for Model Organisms (Shanghai, China). All surgeries were performed under sodium pentobarbital anesthesia which was made to minimize suffering of the mice. The mice were euthanized with CO 2 at the end of the experiments.
Plasmid construction and recombinant protein preparation
A DNA fragment encoding for Amph and the GGGGS-mature TGF-α fusion protein (AGT) was synthesized and subcloned into the NdeI and BamHI restriction enzyme sites of the pET22b(+) vector. The codon sequences were optimized according to Escherichia coli preferences. The recombinant plasmid was named pET22b-AGT. pET22b-Amph, a plasmid coding for Amph only, was also constructed in same way as the control. The primers used for AGT amplification are as follows: forward primer: 5′-CTCGCAGCCATA TGAAACCGAAAGAAG-3′, and reverse primer: 5′-AAAGGA TCCTCAGGCCAGCAGGTC-3′. The pET22b-Amph and pET22b-AGT plasmids were transformed into E. coli BL21 (DE3) host cells (TransGen, Beijing, China). Transformed colonies were selected and cultured in TB broth and protein expression was induced by 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4 h at 37°C until OD 600 reached 2.0. The E. coli cells were harvested and broken by ultrasound in SSB_A (20 mM Tris-HCl, 10 mM EDTA, pH 8.0). The inclusion body was washed with WIBB (20 mM TrisHCl, 1M guanidine-HCl, 65 mM DTT, 2 mM EDTA, pH 8.0) three times and denatured by 6 ml DIBB (20 mM Tris-HCl, 7M guanidine-HCl, 65 mM DTT, 2 mM EDTA, pH 8.0) overnight and refolded in RB (0.5M arginine-HCl, 20 mM Tris-HCl, 0.6-6 mM oxidized glutathione, 1 mM EDTA, pH 9.5). After 48 h of refolding, the protein solution was reloaded on a Q sepharose column (2 cm × 2 cm; Pharmacia, Stockholm, Sweden) with loading buffer (LB; 20 mM Tris-HCl, 1 mM EDTA, pH 10.0) and then eluted with washing buffer (WB; 1M NaCl, 20 mM Tris-HCl, 1 mM EDTA, pH 10.0). The protein and its purity were analyzed by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Cell culture
The A431 human epidermoid carcinoma cell line, A549 human NSCLC cell line, MCF-7 and MDA-MB-468 human adenocarcinoma cell lines were obtained from ATCC (Manassas, USA). The Caski human epidermoid carcinoma cell line, DU145 human prostate carcinoma cell line, Eca109 esophageal and cardia carcinoma, HL60 human acute promyelocytic leukemia, TE1 human esophageal and cardia carcinoma cell line, and U251 human glioma cell line were obtained from the Shanghai Cell Bank, Chinese Academy of Sciences (Shanghai, China). A431, MCF-7, MDA-MB-468, HL60, and U251 cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/High (Gibco, Grand Island, USA; catalog number 11995-065) supplemented with 10% fetal bovine serum (Gibco; catalog number: 10099-141). A549 and DU145 were cultured in F12K (Gibco; catalog number: 21127022) supplemented with 10% fetal bovine serum. Caski, Eca109, and TE1 were cultured in RPMI 1640 medium (Gibco; catalog number: 11875-093) supplemented with 10% fetal bovine serum at 37°C under 5% CO 2 .
Protein heat stability assay
Proteins in PBS solution at 100 μM were treated at 4, 37 or 60°C for 30 days. Then, their heat stability was measured using a MTT assay described as in 'In vitro cytotoxicity assay'. The same proteins stored at −80°C were used as a control.
Real-time PCR detection of EGFR expression
Total RNA was isolated from cultured cells with Trizol following the manufacturer's protocol (Invitrogen Life Technologies, Carlsbad, USA). One microgram of total RNA was used for first strand cDNA synthesis using TransScript ® RT/RI Enzyme Mix (2-
Step RT PCR; TransGen Biotech, Beijing, China) according to the manufacturer's instructions. Real-time PCR was performed using SYBR Green (Roche, Basel, Switzerland) with β-actin as a control to normalize for levels of mRNA expression. The primers used for this analysis are EGFR: forward primer, 5′-TGTGTAACGGAATA GGTATTGGTG-3′; and reverse primer, 5′-GAGGAGTATGTGT GAAGGAGTC-3′; and β-actin: forward primer, 5′-ATTGCTGAC AGGATGCAGAA-3′; and reverse primer, 5′-GCTGATCCACAT CTGCTGGAA-3′.
In vitro cytotoxicity assay
Each well of the 96-well plate was seeded with 90 μl of a cell suspension containing 5000 cells. After overnight culture, 10 μl of protein samples (Amph or AGT) were added into each well and cells were cultured for an additional 72 h. Cytotoxicity was assayed by the MTT method as described previously [17] .
Flow cytometry analysis
Cells grown in 6-well plates were treated with the protein samples. After 24 h, the cells were stained with the Annexin V-Fluorescein isothiocyanate (FITC) Apoptosis Staining/Detection Kit (BD Pharmagen, Franklin Lakes, USA) for 20 min at room temperature. The cells were analyzed using a Guava flow cytometer (Millipore, Billerica, USA), and the data were subsequently analyzed using Flow JO software (TreeStar, Ashland, USA).
In vivo toxicity assay
Naive ICR mice (8-weeks-old) were randomly allocated into seven groups (four per group: two males and two females). Mice were injected intravenously with various doses of Amph (2.9, 5.8, and 11.6 mg/kg) or AGT (4.2, 8.4, and 16.8 mg/kg) every other day for a total of five injections, the control group mice were injected with saline. Body weight changes and visible signs of toxicity such as coating ruffling and changes in gait were detected each day. One week after the final injection, the animals were sacrificed and blood was collected for hematological analysis with a fully automated hematology analyzer (Sysmex CHEMIX-180, Tokyo, Japan). Hematological parameters including alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), blood urea nitrogen (BUN), uric acid (UA), and total bilirubin (T-BIL) were evaluated.
In vivo immunogenicity assay
Naive ICR mice (8-week-olds) were randomly allocated into five groups (six per group: three males and three females), were injected intravenously with various doses of AGT (16.8 and 3.36 mg/kg) or Amph (11.6 and 2.32 mg/kg) per mouse every other week for a total of four injections, the control group mice were injected with saline. Blood samples (200 μl) from the orbital venous plexus were collected each week after the experiment began.
Indirect enzyme-linked immunosorbent assay
Immunogenicity was measured by an indirect enzyme-linked immunosorbent assay (ELISA). Briefly, 96-well low binding polystyrene plates were coated with 50 μl AGT or Amph (10 μg/ml) in 50 mM carbonate buffered saline (CBS, pH 9.6) and incubated overnight at 4°C. After three washes with PBS, the plates were blocked with PBS containing 1% BSA for 2 h at 37°C. After wash with PBS containing 0.05% Tween 20 (PBST), the serum samples were diluted and added in duplicate along with normal serum as a control. After wash with PBST, the plates were incubated with 50 μl HRPconjugated goat-anti-mouse IgG (Beyotime, Shanghai, China) for 1 h at 37°C. Then the plates were washed with PBST and 100 μl of TMB/peroxide mixture was added after 15 min of incubation at room temperature. The enzymatic reaction was stopped by addition of an equal volume of 2 M sulfuric acid, and the product was quantified at OD 450 with an automatic plate reader (Bio-Tek Instruments, Winooski. USA).
In vivo anti-tumor activity assay 
Statistical analysis
Data were shown as the mean ± SEM. Differences between groups were estimated using Student's t-test. Significant differences were accepted when P-values <0.05. The statistical analysis was calculated and plotted using GraphPad Prism version 6.0 (GraphPad Software, Canada).
Results
Expression and purification of Amph and AGT recombinant protein
The plasmid structures of pET22b-Amph/AGT are shown in Fig. 1A and the coding sequence of Amph and TGF-α is shown in Supplementary Material. After expression and purification of the recombinant Amph and AGT proteins, the products were analyzed using 12% SDS-PAGE. As represented in Fig. 1B , single bands of about 13 kDa and 18.9 kDa were observed on SDS-PAGE, respectively. The purity of the final protein products was greater than 95% according to the gray-scanning measurement. AGT exhibits more significant cytotoxicity in vitro on EGFR high-expressing tumor cell lines
Ten human tumor cell lines were divided into EGFR high-/low-expressing groups according to their EGFR relative expression levels assessed by real-time PCR as shown in Fig. 2 . In vitro anti-tumor effects of Amph and AGT on EGFR high/low-expressing human tumor cell lines were analyzed by MTT assay and the data are shown in Fig. 3 . The results showed that the TGF-α-mediated EGFR targeting dramatically increased the cytotoxicity of Amph against EGFR high-expressing cell lines (Fig. 3A) but had less effect on EGFR low-expressing cell lines (Fig. 3B) . AGT exhibited an enhanced at least 500-folds cytotoxicity in four of five EGFR high-expressing tumor cell lines. However, AGT showed no difference with Amph on the DU145 human prostate carcinoma cell line, although it is one of the five EGFR highexpressing cell lines. Meanwhile, in the five EGFR low-expressing tumor cell lines, AGT did not show significantly increased cytotoxicity relative to Amph. The data were shown in Table 1 .
AGT exhibits more significant apoptosis in vitro on EGFR high-expressing tumor cell lines
To explore how AGT influences the viability and apoptosis of the tumor cells, we incubated 30 μM AGT or Amph with EGFR high-or low-expressing tumor cells for 48 h. The percentage of alive and apoptotic cells was evaluated using a Annexin V-FITC Apoptosis Detection Kit by flow cytometry. The results showed that the number of late apoptotic cells was significantly increased in EGFR high-expressing cell lines (except DU145) after treatment with AGT, when compared those treated with Amph (Fig. 4A) , which was not observed in EGFR low-expressing cell line (Fig. 4B) .
AGT exhibits unusual thermostability
The heat stability of AGT and Amph was tested. The cytotoxic activity against the MDA-MB-468 cell line was tested after the protein samples were treated at different temperatures for 30 days. Even though they were treated at 60°C, the activity of AGT and Amph was not significantly decreased (Fig. 5) . The IC 50 values are shown in Table 2 . These data indicated AGT was similar to Amph with unusual thermostability.
AGT exhibits stronger tumor inhibition effect on EGFR high-expressing cancer cells in vivo
The anti-tumor effect of AGT and Amph was tested in vivo in a xenograft nude-mice model generated using the MDA-MB-468 cell line. Drug administration with an osmotic pump releasing, 0.5 μl/h was initiated from Day 18 after tumor inoculation. The volume of the tumors was measured twice a week until the mice were ). Q2, early apoptosis cell; Q4, late apoptosis cell. **P < 0.01, and ***P < 0.001. sacrificed. On the day, the mice were sacrificed, the mean volume of the tumors in the AGT high-dose group (34.1 mg/kg, 1.8 μmol/kg) was 95.34 ± 34.95 mm 3 , the AGT low-dose group (3.41 mg/kg, 0.18 μmol/kg) was 195.86.7 ± 55.65 mm 3 , and the Amph group (23.6 mg/kg, 1.8 μmol/kg) was 332.95 ± 23.77 mm 3 , which were significantly lower than that in the control group which was 575.26 ± 75.72 mm 3 (P < 0.05; Fig. 6A ). The mean body weight of all the drug-treated group mice just slightly changed in comparison with that of the control group mice (Fig. 6B) .
AGT exhibits low toxicity in mice
In naive ICR mice, five intravenous injections with different doses of Amph (2.9 mg/kg, 5.8 mg/kg, and 11.6 mg/kg) and AGT (4.2 mg/kg, 8.4 mg/kg, and 16.8 mg/kg) resulted in no significant loss of body weight (Fig. 7A ) and no death of the animals. Gross pathological examination of the mice indicated that the liver and spleen were normal in color and the usual in size (data not shown). Serum samples from the treated mice showed no significant change in the levels of ALP, ALT, AST, BUN, T-BIL, and UA (Fig. 7B) , when compared with those of the control mice, indicating no significant liver or kidney toxicity.
AGT exhibits low immunogenicity in mice
To investigate the immunogenicity of AGT and Amph, ICR mice were subject to four i.v. injections with different doses of AGT (16.8 and 3.36 mg/kg) or Amph (11.6 and 2.32 mg/kg), and serum was collected for analysis each week. The data showed that the production of antibodies against AGT or Amph were quite low after the fourth dose. AGT showed no significant difference in immunogenicity compared with Amph at doses of 884 and 177 nmol/kg (Fig. 8) .
Discussion
It is a major development in the tumor therapy field to search for active anti-tumor activity among natural proteins and their modified forms. These proteins should have high selectivity and efficiency, with low toxicity and immunogenicity. Amph derived from R. pipiens oocytes is a good research object which meets these requirements. We created a fusion protein AGT which is composed of amphinase and TGF-α using genetic engineering, and used a recombinant Amph protein for comparison. The activities of these two recombinant proteins were tested in 10 different types of cancer cell lines with high-EGFR expression and low-EGFR expression [15, [18] [19] [20] [21] . In vitro experiments showed that in the EGFR-high expression cell lines, the cytotoxicity of AGT was 500-8000-folds higher than that of Amph except in the prostate cancer cell line DU145, while AGT had no significant effect on the EGFR low expression cell lines, except the breast cancer cell MCF-7. These data suggest that the targeting effect of TGF-α can increase the cytotoxic effect of Amph in EGFR high-expressing cell lines. The results of apoptotic tests also showed that in the EGFR-high expression cell lines, the number of apoptotic cells was significantly higher than that in the Amph and negative control, except the prostate cancer cell line DU145.
In the in vivo experiment, we selected the sensitive breast cancer cell line MDA-MB-468 as a tumor-bearing model. Drug administration results showed that the AGT group had a better tumor suppressing effect than Amph under the same doses, suggesting that the auxiliary targeting effect of TGF-α in AGT enhanced its anti-tumor activity.
The anti-tumor potential of AGT also lies in its own conformation characteristics. A thermostability test showed that the cytotoxic activity of AGT and Amph remained unchanged after exposure to 4, 37, or 60°C for 30 days, which indicated that AGT and Amph had similar thermostability.
The results of the drug toxicity test showed no deaths among the mice after five intravenous administration of AGT or Amph at the highest doses. Biochemical indexes in the treated mice showed no significant differences compared with the saline treated control mice, indicating that the toxicity of both the fusion protein AGT and Amph is low.
It is noteworthy that capsule sustained-release administration is equivalent to 1/7 of the maximum dose in acute trials and the intravenous dose is twice the dose of the intraperitoneal dose. Therefore, the therapeutic doses we used are safe. An immunogenicity test was performed on blood samples taken weekly for 8 consecutive weeks after the first intravenous administration. The antibody dilution fold levels were detected during the 5th week in the high-dose group and during the 8th week in the low-dose group after first administration. No significant difference was found in the antibody titers between AGT and Amph. Thus, AGT and Amph show similar characteristics in anti-tumor sensitivity, toxicity, immunogenicity, and thermostability, but AGT has more targeting capability.
Targeted anticancer drugs are a promising therapeutic treatment in current clinical cancer therapy. Our results showed that the recombinant targeting protein AGT can greatly improve its targeting anti-tumor effect, as a result of fusion TGF-α with Amph, while keeping its low toxicity and immunogenicity. We believe that there is great therapeutic potential to utilize Amph as a template for an immunizing nuclease. We plan to further investigate the anti-tumor activity and mechanism of this immunoRNasein and hope that it can be used to treat cancers with high-EGFR expression level.
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